Slide1 l.jpg
Sponsored Links
This presentation is the property of its rightful owner.
1 / 40

Endoluminal Duodenal - Jejunal Sleeve , Fat Reduction ... And the Future Francesco Rubino , MD Chief , Section of Gastrointestinal Metabolic Surgery PowerPoint PPT Presentation


  • 688 Views
  • Uploaded on
  • Presentation posted in: General

Endoluminal Duodenal - Jejunal Sleeve , Fat Reduction ... And the Future Francesco Rubino , MD Chief , Section of Gastrointestinal Metabolic Surgery Director ; Diabetes Surgery Center Weill Cornell Medical College - New York Presbyterian Hospital New York, NY USA.

Download Presentation

Endoluminal Duodenal - Jejunal Sleeve , Fat Reduction ... And the Future Francesco Rubino , MD Chief , Section of Gastrointestinal Metabolic Surgery

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


EndoluminalDuodenal-JejunalSleeve, Fat Reduction... And the Future

Francesco Rubino, MD

Chief, Section of GastrointestinalMetabolicSurgery

Director; DiabetesSurgeryCenter

Weill CornellMedicalCollege- New York PresbyterianHospital

New York, NY USA

First Canadian Summit on Metabolic Surgery for T2DM

Montreal, May 6-7, 2010


METHODS

Intraluminal Duodenal Sleeve


Controls: Fenestrated Duodenal Sleeve


Fig 1 b


Goto-Kakizaki Rat (GK)

  • Complete tube (n=12)

  • Fenestrated Tube (n=12)

  • No tube (Sham) (n=6)

    2 & 3 pair-fed to 1


OGTT

AUC: P< 0.01


« Larry »


« Larry »


« Larry »


« Larry »


« Larry »


GK Rats: GIP-Response to Glucose


Wistar Rats: GIP-Response to Glucose


ELS Improves IP Glucose Tolerance (Kaplan et al)


Endoluminal Sleeve - EndoBarrier™

Food bypasses the duodenum and proximal jejunum

CONFIDENTIAL


Week 1 Data Summary

EndoBarrier™ Diabetes Trial (Chile)

*Food intake held identical


EndoBarrier™ Improves HbA1c

EndoBarrier™ Diabetes Trial (Chile)

Week 12

Week 30

N=9

N=4

N=8

N=3

*Week 30 p=0.004


Endoluminal Sleeve: Mechanisms

  • Isolation of Duodenal Mucosa from Nutrients Contact

  • Bile isolated from nutrients

  • No expedited delivery of nutrients to the distal gut


Endoluminal Sleeve: Clinical Applications

  • Primary Therapy of Diabetes ?

    • Long-term ?

    • BMI> 35 ?

    • BMI < 35 ?

  • Diagnostic value ?

  • Pre-surgical Test to select candidates for gastric bypass surgery

  • Integrated Interventional-Drug approach

    • “Adjuvant Therapy”


EndoBarrier Weight Loss Results At 6 Months


EndoBarrier Glucose Improvement at 6 Months


Surgery, Adiposity and Diabetes

Liposuction does not improve diabetes

Surgical resection of greater omentum does not resolve diabetes

S. Klein et al. (ADA 2009)


Metabolic Surgery… the future

  • Multidisciplinary approach and guidelines/standards of care development


Annals of Surgery; March 2010


DSS Reccommendations are

Endorsed by:

ASMBS

IFSO

The Obesity Society (TOS)

Int. Ass Study of Obesity (IASO)

Diabetes UK


  • Bariatric surgery should be considered for adults with BMI > 35 kg/m2 and type 2 diabetes, especially if the diabetes is difficult to control with lifestyle and pharmacologic therapy. (B)

  • Surgery should be considered in pts with BMI > 35 and inadequately controlled diabetes.


  • in patients with type 2 diabetes and BMI of 30–35kg/m2, there is currently insufficient evidence to generally recommend surgery in patients with BMI35 kg/m2 outside of a research protocol.

  • Surgery may be considered as a non-primary alternative in pts with uncontrolled diabetes and BMI 30-35.


Metabolic Surgery… the future

  • Solving the BMI issue…


DSS- BMI

  • Controlled clinical trials in these patients should be performed to determine the safety and efficacy of GI metabolic surgery (A) as well as to identify parameters other than BMI as criteria for appropriate patient selection (A).

SAME LANGUAGE IN ADA’ STANDARDS OF CARE DOCUMENT


Diabetologia 1996


Metabolic Surgery… the future

  • Solving the BMI issue…

  • Diabetes-specific criteria for surgical indication

  • Risk-Stratification in diabetes

  • Improve Standards of Clinical Research


Patient Factors and Outcomes Associated with T2DM Resolution (N=191)

Schauer et al. Annals of Surgery Oct 2003


The “Bad Reputation” of Bariatric Surgery

* Any Textbook


DSS- Research

  • Randomized controlled trials are strongly encouraged to assess the utility of GI surgery to treat T2DM (A). In patients with BMI <35 kg/m2, determining the appropriate use of GI surgery for the treatment of T2DM is an important research priority (A).


Worldwide Consortium for RandomizedClinical Trials in DiabetesSurgery

(WORLDCords)

Diabetes Surgery Center

Weill CornellMedicalCollege-New York PresbyterianHospital


Cornell’s Study

RYGB (Lap)

vs

MedicalTherapy and Lifestyle Modification

PI: Francesco Rubino

SteeringCommittee: H. Lebovitz, J. Buse, A. Goldfine, J. Roth B. Zinman, B. Wolfe, JP Despres, S. Belle


Participating Countries

REGIONAL Chapters:

  • Europe (centers already available in Italy, Netherlands, Belgium, Spain, England,)

  • South-Central America (Mexico?, Brasil, Argentina, Chile, Venezuela,)

  • North America (Cornell, Tuffs, Univ. of Maryland, Mount Sinai?)

  • Asia (Philippines, India, Taiwan, Japan)

  • Middle East (Quatar, UAE, SA)


International Consortium for Diabetes Surgery

Weill Cornell –NYP

Study (50 pts)

US Multicenter Study

200 patients

Worldwide Consortium for RCT

500-800 pts


Metabolic Surgery… the future

  • Solving the BMI issue…

  • Diabetes-specific criteria for surgical indication

  • Risk-Stratification in diabetes

  • Improve Standards of Clinical Research

  • Elucidation of Mechanisms of Action

    • Novel Surgical Procedures

    • Endoluminal Approaches

    • Novel Targets for Drugs

      Re-thinking of Diabetes and Obesity


  • Login